An X-linked severe combined immunodeficient (SCID) patient received a nonirradiated erythrocyte transfusion and developed transfusion-associated graft-versus-host disease (TAGVHD), which was controllable with highdose corticosteroids. Haplo-identical SCT was performed, after a myeloablative conditioning regimen. At day þ 26, he developed GVHD. Chimerism studies revealed DNA of the erythrocyte transfusion donor (ETD) and recipient only. Because of early nonengraftment and the presence of alloreactive T cells of ETD origin, the patient was treated with an immunosuppressive conditioning regimen followed by a second SCT from the same donor. While tapering immunosuppression, he again developed mild GVHD, and DNA of ETD and bone marrow donor origin were both present. On cyclosporin, the ETD-DNA signal finally disappeared. High-resolution HLA typing revealed haploidentity between BMD, ETD and the patient, which might have contributed to the relative mild course of the TAGVHD.
ease; X-linked disease Transfusion-associated graft-versus host disease (TAGVHD) has a high mortality rate in the immunocompromised host due to impaired elimination of the alloreactive, erythrocyte transfusion-derived lymphocyte. 1, 2 Usually, the fatal outcome of TAGVHD is explainable by the delay in diagnosis of the underlying immunodeficiency and therefore delayed institution of immunosuppressive therapy. Some case reports have demonstrated that TAGVHD in severe combined immunodeficient (SCID) patients can be treated successfully by allogeneic bone marrow transplantation. 3 Fatal TAGVHD was observed in immunocompetent patients, transfused with blood from donors homozygous for a shared haplotype with the recipient. 2, 4 Here we describe a favorable course of TAGVHD in a boy with X-linked SCID. 5 Despite intensive conditioning and haplo-identical bone marrow transplantation, erythrocyte transfusion-derived lymphocytes showed prolonged survival and were able to cause two subsequent episodes of TAGVHD. High-resolution typing revealed striking haplo-identity between patient, bone marrow donor and erythrocyte transfusion donor in HLA-B8, HLA-DRB1 and DRB3. 6 Furthermore, the bone marrow donor was homozygous at these HLA loci. It remains unclear why in this case the clinical course was favorable, while TAGVHD is usually fatal in immunocompromised patients.
Case report
A 7-month-old boy was admitted elsewhere because of eczema, failure to thrive and bilateral pneumonia. Cultures obtained by broncho-alveolar lavage revealed Klebsiella pneumoniae but not Pneumocystis carinii. Because of poor general condition and anemia, he received a nonirradiated erythrocyte transfusion (day À40). At 10 days after the erythrocyte transfusion, an agammaglobulinemia was diagnosed and the patient was transferred to our hospital. A diagnosis of X-linked SCID, with T-B þ NKÀ phenotype was made. At that time, his lymphocyte subsets were: CD3 þ , 40/ml; CD20 þ , 900/ml; CD56 þ , absent. His IgG was 0.1 g/l, IgM 0.8 g/l. IgA was absent. The diagnosis of X-SCID was confirmed by molecular analysis of the common g-chain gene, showing a single nucleotide (A) insertion at position 967 in exon 3 of the common g-chain, which resulted in a frameshift.
At 2 weeks after the erythrocyte transfusion (day À27), the patient developed acute GVHD grade II of the skin. This was controllable with steroids, initial dose of 5 mg/kg slowly tapering to less than 1 mg/kg. During the acute GVHD, his CD3 þ lymphocyte count rose to 830/ml, indicating proliferation of immunocompetent lymphocytes, causing GVHD. Chimerism studies of these lymphocytes showed the presence of DNA from the erythrocyte transfusion donor (ETD) as well as DNA of persisting maternal lymphocytes in a ratio of ETD:maternal lymphocytes 90:10.
After 3 weeks, he underwent a haplo-identical PBSCT (day 0) from the mother. The graft contained 12 Â 10 6 /kg CD34 þ cells and 0.15 Â 10 5 /kg CD3 þ cells. To eliminate persisting lymphocytes from the ETD, the patient was treated with one course of rabbit ATG (Merieux, France; 5 mg/kg) on day À9 prior to conditioning with busulfan 2.5 mg/kg orally twice daily on days À8 to À4 and cyclophosphamide 50 mg/kg once daily i.v. (day À4 to À1). Graft-versus-host prophylaxis consisted of cyclosporin (2 mg/kg i.v. twice daily starting on day À1). On day þ 26, he again developed GVHD of skin concomitantly with a sharp rise in the peripheral lymphocyte count (nondetectable o5/ml to 150/ml in 2 days). This was again adequately controllable with corticosteroids (1 mg/kg/day). Chimerism studies on peripheral blood mononuclear cells and bone marrow at that time showed DNA of recipient and ETD origin, but not of SCT donor origin. The bone marrow aspirate yielded a low number of cells with hardly any progenitor cells detectable. This early graft-failure and a second episode of GVHD, apparently due to allo-reactive lymphocytes of ETD origin, were treated by immunosuppression and a second SCT on day þ 39. Bone marrow from the same donor was used as the stem cell source. The graft contained 25 Â 10 6 /kg CD34 þ cells and 1.6 Â 10 5 /kg CD3 þ cells. The conditioning regimen consisted of immunosuppression by OKT-3 (max. dose of 5 mg, followed by a tapering schedule) and high-dose methylprednisolone (20 mg/kg Â 4 days, with a subsequent tapering schedule).
On day þ 61, he showed full donor chimerism in both myeloid and lymphoid lineages. At that time, ETD DNA could not be detected. However, on day þ 75, 1 week after steroids and OKT3 were stopped, mild GVHD symptoms (rash and diarrhoea) reappeared. At that time, 10-30% of mononuclear cells again were of ETD origin. A skin biopsy taken at that time was analyzed and also revealed the ETD signal.
Mixed lymphocyte culture was performed between cells of the patient and fresh peripheral blood lymphocytes from the ETD. A low proliferative response of patient lymphocytes to irradiated ETD cells, as well as to nonrelated control donor cells, was observed. Notably, cells of the ETD also showed an almost negative response to irradiated patient cells (Table 1) . We therefore performed DNA-based HLA typing, which revealed haplo-identity at HLA-B, DRB1 and DRB3 between BMT and ETD ( Table 2) .
Owing to the reappearance of ETD cells, cyclosporin was administered and very slowly tapered over 6 months, while the ETD signal gradually disappeared. From that time onwards, chimerism studies remained fully donor. His lymphocyte counts and function normalized 6 months after the second BMT (day þ 210, Figure 1 ). 
TAGVHD in SCID
He is currently clinically well, with no signs of GVHD after an uneventful follow-up of 24 months.
Discussion
We describe the complex interplay in a SCID patient between erythrocyte transfusion originating lymphocytes, maternal lymphocytes and bone marrow-derived maternal lymphocytes in a setting of HLA haploidentity. This child developed TAGVHD after a nonirradiated erythrocyte transfusion, which is usually fatal. Prompt recognition and institution of high-dose immunosuppression might have contributed to the favorable clinical course.
In contrast to data in literature, 2 our patient did not develop cytopenia during this episode of TAGVHD, but instead had a notable increase in the number of lymphocytes which were of mainly of ETD origin. Despite intensive myeloablative conditioning, intensified by one dose of ATG, this patient developed a second episode of GVHD 3 weeks after SCT. At that moment, no donor marrow DNA was detectable, in either peripheral blood or bone marrow. ETD DNA was present in the bone marrow, but this might have been due to contamination by small amounts of peripheral blood lymphocytes. At that time, the bone marrow was poor in cell numbers with a very low count of progenitor cells. Graft failure was diagnosed and the patient underwent a second SCT with immunosuppressive conditioning. While tapering the immunosuppression, a third episode of GVHD occurred in conjunction with ETD lymphocytes.
Survival of immunocompetent ETD lymphocytes despite intensive conditioning is poorly understood. Knobloch et al 7 described stable engraftment of allogeneic T lymphocytes in a SCID patient after a nonirradiated erythrocyte transfusion, but these lymphocytes did not cause GVHD and were very sensitive to treatment with ATG.
However, these sensitized T lymphocytes of ETD origin might have been the cause of the graft failure after the first PSCT. This phenomenon was described in a murine model with F1 hybrid mice that rejected a marrow graft from one but not the other parent, indicating an immune recognition in the rejection process, which is called 'hybrid resistance'. 8 Initially, we explained the clinical picture of severe TAGVHD as a result of the combined alloreactivity of ETD and maternal T lymphocytes both directed against the patient. Alloreactivity between ETD and maternal cells would further amplify this reaction. It was thus surprising that the MLC between the ETD and irradiated patient cells yielded negative results (Table 1) .
Subsequently, HLA typing of patient, BMD and ETD, a nonrelated individual living in the same general area of the Netherlands was performed and revealed haplo-identity on HLA-B, HLA-DR1 and DR-3, whereas the BMD was homozygous at these loci ( Table 2) .
As mentioned before, homozygosity of erythrocyte transfusion-derived lymphocytes increases the risk of TAGVHD in a heterozygous recipient. According to the HLA-A mismatch, the ETD HLA-A23 is considered immunogenic to HLA-A3 recipients.
9 This is in contradiction to the relatively mild clinical course in our patient.
The ETD signal disappeared with immunosuppressive therapy. Due to three episodes of GVHD, the ETD lymphocytes underwent intensive proliferation, which probably leads to increased aging of cells. Stably engrafted bone marrow-derived lymphocytes finally eradicated the ETD lymphocytes.
In conclusion, a nonirradiated erythrocyte transfusion led to a very mild course of TAGVHD in a SCID patient. Despite intensive conditioning, prolonged survival of the erythrocyte transfusion-derived lymphocytes was responsible for two episodes of GVHD. The manner in which the shared HLA haploidentity contributed to the clinical course remains unclear. 
